Evidence map›Paper›PMID 33922806›Full record

ArticleCells2021

Chemical Inhibitors of Dynamin Exert Differential Effects in VEGF Signaling.

Dimitris Basagiannis, Sofia Zografou, Evangeli Goula, Despoina Gkeka, Evangelos Kolettas, Savvas Christoforidis

Open access · goldAbstract read
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. LDL receptor-mediated endocytosis ofProceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Small molecules targeting endocytic uptake and recycling pathways.Frontiers in cell and developmental biology · 2023
    Review
  8. Review
  9. The orchestrated signaling by PI3Kα and PTEN at the membrane interface.Computational and structural biotechnology journal · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Dimitris BasagiannisDepartment of Biomedical Research, Foundation for Research and Technology, Institute of Molecular Biology and Biotechnology, 45110 Ioannina, Greece.ORCID 0000-0002-3932-5051
Sofia ZografouDepartment of Biomedical Research, Foundation for Research and Technology, Institute of Molecular Biology and Biotechnology, 45110 Ioannina, Greece.
Evangeli GoulaDepartment of Biomedical Research, Foundation for Research and Technology, Institute of Molecular Biology and Biotechnology, 45110 Ioannina, Greece.
Despoina GkekaDepartment of Biomedical Research, Foundation for Research and Technology, Institute of Molecular Biology and Biotechnology, 45110 Ioannina, Greece.
Evangelos KolettasDepartment of Biomedical Research, Foundation for Research and Technology, Institute of Molecular Biology and Biotechnology, 45110 Ioannina, Greece.
Savvas ChristoforidisDepartment of Biomedical Research, Foundation for Research and Technology, Institute of Molecular Biology and Biotechnology, 45110 Ioannina, Greece.
University of Ioannina · GR

Funding

European Regional Development Fund, Advanced Research Activities in Biomedical and Agro alimentary Technologies, KRHPIS MIS 5002469European Regional Development Fund, BioImaging-GR: The Greek Research Infrastructure for the Imaging and Monitoring of Fundamental Biological Processes MIS 5002755European Regional Development Fund, EDBM34 MIS5004410State Scholarships Foundation, IKY Research Projects for Excellence
6 · The paper itself

Abstract

VEGFR2 is the main receptor and mediator of the vasculogenic and angiogenic activity of VEGF. Activated VEGFR2 internalizes through clathrin-mediated endocytosis and macropinocytosis. As dynamin is a key regulator of the clathrin pathway, chemical inhibitors of dynamin are commonly used to assess the role of the clathrin route in receptor signaling. However, drugs may also exert off-target effects. Here, we compare the effects of three dynamin inhibitors, dynasore, dyngo 4a and dynole, on VEGFR2 internalization and signaling. Although these drugs consistently inhibit clathrin-mediated endocytosis of both transferrin (a typical cargo of this route) and VEGFR2, surprisingly, they exert contradictory effects in receptor signaling. Thus, while dynasore has no effect on phosphorylation of VEGFR2, the other two drugs are strong inhibitors. Furthermore, although dyngo does not interfere with phosphorylation of Akt, dynasore and dynole have a strong inhibitory effect. These inconsistent effects suggest that the above dynamin blockers, besides inhibiting dynamin-dependent endocytosis of VEGFR2, exert additional inhibitory effects on signaling that are independent of endocytosis; i.e., they are due to off-target effects. Using a recently developed protocol, we comparatively validate the specificity of two endocytic inhibitors, dynasore and EIPA. Our findings highlight the importance of assessing whether the effect of an endocytic drug on signaling is specifically due to its interference with endocytosis or due to off-targets.

Indexed as

AcrylamidesClathrinDynaminsEndocytosisGene Expression RegulationHumansHuman Umbilical Vein Endothelial CellsHydrazonesIndolesNaphtholsVascular Endothelial Growth Factor A2-cyano-N-octyl-3-(1-(3-dimethylaminopropyl)-1H-indol-3-yl)acrylamideAcrylamidesClathrinDynaminsdyngo-4aHydrazonesIndolesN'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazideNaphtholsVascular Endothelial Growth Factor AVEGFA protein, humancell signalingdynaminendocytosisendothelial cell biologyinhibitorsvesicular trafficking

Identifiers

PMID33922806
PMCPMC8145957
OpenAlexW3158084159

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.